Size | Price | |
---|---|---|
100mg | ||
250mg | ||
500mg |
ln Vitro |
Norathyrol (1-25 µM) stops JB6 P+ cells from growing by causing a cell cycle arrest. Norathyrol causes G2-M arrest, which stops JB6 cell development [3]. In JB6 P+ cells, northyronol prevents UVB-induced ERK phosphorylation, AP-1, and NF-κB activation [3] [WB cell growth assay].
|
---|---|
ln Vivo |
Northiol is a natural metabolite of mango in the human gut and is oral effective and safe [1]. Northyronol (0.92, 1.85 and 3.7 mg/kg) dose-dependently lowered serum uric acid levels by 27.0%, 33.6 and 37.4%, respectively [4].
|
Cell Assay |
cell viability assay [3]
Cell Types: Mouse skin epidermis JB6 P+ cells Tested Concentrations: 0 , 1, 10 or 25 µM Incubation Duration: 24 or 72 hrs (hours) Experimental Results: Inhibits cell growth in a dose- and time-dependent manner without causing cell death. Western Blot Analysis[3] Cell Types: JB6 P+ Cell Tested Concentrations: 0, 1, 10 or 25 µM Incubation Duration: 2 hrs (hours) Experimental Results: Inhibition of UVB-induced ERK and p90RSK phosphorylation. |
Animal Protocol |
Animal/Disease Models: Adult Kunming mice, body weight 18-22 g[4]
Doses: 0.92, 1.85 and 3.7 mg/kg Route of Administration: intragastric (po) (po)administration; twice a day for a total of five times. Experimental Results: Serum uric acid levels diminished by 27.0% respectively. , 33.6% and 37.4%. |
References |
[1]. Zhi-Long Shi, et al. In Vitro and In Vivo Effects of Norathyriol and Mangiferin on α-Glucosidase. Biochem Res Int. 2017;2017:1206015.
[2]. Ashley S Wilkinson,et al. Effects of the mango components mangiferin and quercetin and the putative mangiferin metabolite norathyriol on the transactivation of peroxisome proliferator-activated receptor isoforms. J Agric Food Chem. 2008 May 14;56(9):3037-42. [3]. Jixia Li, et al. Norathyriol suppresses skin cancers induced by solar ultraviolet radiation by targeting ERK kinases. Cancer Res. 2012 Jan 1;72(1):260-70. [4]. Yanfen Niu, et al. Hypouricaemic action of mangiferin results from metabolite norathyriol via inhibiting xanthine oxidase activity. Pharm Biol. 2016 Sep;54(9):1680-6. |
Molecular Formula |
C13H8O6
|
---|---|
Molecular Weight |
260.20
|
CAS # |
3542-72-1
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
C1=C(C=C2C(=C1O)C(=O)C3=CC(=C(C=C3O2)O)O)O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~384.32 mM)
H2O : < 0.1 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.8432 mL | 19.2160 mL | 38.4320 mL | |
5 mM | 0.7686 mL | 3.8432 mL | 7.6864 mL | |
10 mM | 0.3843 mL | 1.9216 mL | 3.8432 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.